# Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

> **NCT03772925** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 18 (actual)

## Conditions studied

- Recurrent Acute Myeloid Leukemia
- Recurrent Myelodysplastic Syndrome
- Refractory Acute Myeloid Leukemia
- Refractory Myelodysplastic Syndrome

## Interventions

- **DRUG:** Belinostat
- **DRUG:** Pevonedistat

## Key facts

- **NCT ID:** NCT03772925
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-20
- **Primary completion:** 2022-09-06
- **Final completion:** 2025-05-08
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Drug supply issues
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03772925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03772925, "Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-08-16 from https://api.ai-analytics.org/clinical/NCT03772925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*